161 related articles for article (PubMed ID: 28063221)
21. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
Amacher DE
Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
[TBL] [Abstract][Full Text] [Related]
22. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
23. Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.
Maida M; Macaluso FS; Salomone F; Petta S
Curr Mol Med; 2016; 16(8):721-737. PubMed ID: 27719652
[TBL] [Abstract][Full Text] [Related]
24. Liver fibrosis markers of nonalcoholic steatohepatitis.
Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
[TBL] [Abstract][Full Text] [Related]
25. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
Wu G; Li H; Fang Q; Zhang J; Zhang M; Zhang L; Wu L; Hou X; Lu J; Bao Y; Jia W
Sci Rep; 2017 Jul; 7(1):5095. PubMed ID: 28698650
[TBL] [Abstract][Full Text] [Related]
26. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD.
Wang J; Li P; Jiang Z; Yang Q; Mi Y; Liu Y; Shi R; Zhou Y; Wang J; Lu W; Li S; Liu D
Korean J Intern Med; 2016 May; 31(3):479-87. PubMed ID: 27025268
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers in nonalcoholic fatty liver disease.
Neuman MG; Cohen LB; Nanau RM
Can J Gastroenterol Hepatol; 2014 Dec; 28(11):607-18. PubMed ID: 25575111
[TBL] [Abstract][Full Text] [Related]
29. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.
Goh GB; Issa D; Lopez R; Dasarathy S; Dasarathy J; Sargent R; Hawkins C; Pai RK; Yerian L; Khiyami A; Pagadala MR; Sourianarayanane A; Alkhouri N; McCullough AJ
J Gastroenterol Hepatol; 2016 May; 31(5):995-1000. PubMed ID: 26589761
[TBL] [Abstract][Full Text] [Related]
30. How to Diagnose Nonalcoholic Fatty Liver Disease.
de Alwis NM; Anstee QM; Day CP
Dig Dis; 2016; 34 Suppl 1():19-26. PubMed ID: 27547937
[TBL] [Abstract][Full Text] [Related]
31. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
Kazankov K; Barrera F; Møller HJ; Rosso C; Bugianesi E; David E; Younes R; Esmaili S; Eslam M; McLeod D; Bibby BM; Vilstrup H; George J; Grønbaek H
Liver Int; 2016 Oct; 36(10):1549-57. PubMed ID: 27102725
[TBL] [Abstract][Full Text] [Related]
32. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
[TBL] [Abstract][Full Text] [Related]
33. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
34. 13C-Methacetin Breath Testing in Patients with Non-Alcoholic Fatty Liver Disease.
Kempiński R; Neubauer K; Wieczorek S; Dudkowiak R; Jasińska M; Poniewierka E
Adv Clin Exp Med; 2016; 25(1):77-81. PubMed ID: 26935501
[TBL] [Abstract][Full Text] [Related]
35. Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease.
Marzuillo P; Grandone A; Perrone L; Miraglia Del Giudice E
World J Gastroenterol; 2015 Jun; 21(21):6444-50. PubMed ID: 26074683
[TBL] [Abstract][Full Text] [Related]
36. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
Boursier J; Vergniol J; Guillet A; Hiriart JB; Lannes A; Le Bail B; Michalak S; Chermak F; Bertrais S; Foucher J; Oberti F; Charbonnier M; Fouchard-Hubert I; Rousselet MC; Calès P; de Lédinghen V
J Hepatol; 2016 Sep; 65(3):570-8. PubMed ID: 27151181
[TBL] [Abstract][Full Text] [Related]
38. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
[TBL] [Abstract][Full Text] [Related]
39. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
Liang J; Han T; Gao YT; Jing L; Ma Z
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4123-9. PubMed ID: 26592838
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver diseases: update on the challenge of diagnosis and treatment.
Oh H; Jun DW; Saeed WK; Nguyen MH
Clin Mol Hepatol; 2016 Sep; 22(3):327-335. PubMed ID: 27729634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
